更新于：2024-11-04
Doxapram Hydrochloride
盐酸多沙普仑
更新于：2024-11-04
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1965-06-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H33ClN2O3 |
InChIKeyZOMBFZRWMLIDPX-UHFFFAOYSA-N |
CAS号7081-53-0 |
关联
20
项与 盐酸多沙普仑 相关的临床试验A Phase 1, Randomized, Double-blind, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QEV-817 Oral Suspension in Healthy Volunteers
Oral Doxapram for Apnoea of Prematurity: Dosage Study in Preterm Infants
Comparative study of the effect of caffeine and doxapram on respiratory parameters of patients admitted to intensive care units after spinal surgery
100 项与 盐酸多沙普仑 相关的临床结果
登录后查看更多信息
100 项与 盐酸多沙普仑 相关的转化医学
登录后查看更多信息
100 项与 盐酸多沙普仑 相关的专利（医药）
登录后查看更多信息
558
项与 盐酸多沙普仑 相关的文献（医药）2024-07-01Archives of disease in childhood. Fetal and neonatal edition
Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5–6 years
Article
作者: Jarreau, Pierre-Henri ; Marchand-Martin, Laetitia ; Onland, Wes ; Saade, Lauren ; Ancel, Pierre Yves ; Benhammou, Valérie ; Pierrat, Véronique ; Tréluyer, Ludovic ; Zana-Taieb, Elodie ; Torchin, Héloïse ; Kuhn, Pierre ; Letouzey, Mathilde
Objective:
To assess the long-term neurodevelopmental impact of doxapram for treating apnoea of prematurity.
Design:
Secondary analysis of the French national cohort study EPIPAGE-2. Recruitment took place in 2011. A standardised neurodevelopmental assessment was performed at age 5–6 years. A 2:1 propensity score matching was used to control for the non-randomised assignment of doxapram treatment.
Setting:
Population-based cohort study.
Patients:
All children born before 32 weeks’ gestation alive at age 5–6 years.
Interventions:
Blind and standardised assessment by trained neuropsychologists and paediatricians at age 5–6 years.
Main outcome measures:
Neurodevelopmental outcomes at age 5–6 years assessed by trained paediatricians and neuropsychologists: cerebral palsy, developmental coordination disorders, IQ and behavioural difficulties. A composite criterion for overall neurodevelopmental disabilities was built.
Results:
The population consisted of 2950 children; 275 (8.6%) received doxapram. Median (IQR) gestational age was 29.4 (27.6–30.9) weeks. At age 5–6 years, complete neurodevelopmental assessment was available for 60.3% (1780 of 2950) of children and partial assessment for 10.6% (314 of 2950). In the initial sample, children receiving doxapram had evidence of greater clinical severity than those not treated. Doxapram treatment was associated with overall neurodevelopmental disabilities of any severity (OR 1.43, 95% CI 1.07 to 1.92, p=0.02). Eight hundred and twenty-one children were included in the 2:1 matched sample. In this sample, perinatal characteristics of both groups were similar and doxapram treatment was not associated with overall neurodevelopmental disabilities (OR 1.09, 95% CI 0.76 to 1.57, p=0.63).
Conclusions:
In children born before 32 weeks’ gestation, doxapram treatment for apnoea of prematurity was not associated with neurodevelopmental disabilities.
2023-11-01Journal of veterinary pharmacology and therapeutics
The effect of doxapram on survival and APGAR score in newborn puppies delivered by elective caesarean: A randomized controlled trial
Article
作者: Bowden, Ross S ; Metcalfe, Steven S ; Tuke, S Jonathan ; Kordzakhia, Nino ; Musk, Gabrielle C ; Fretwell, Shelby ; Hyndman, Timothy H ; Irons, Peter C ; Mosing, Martina ; Aleri, Joshua W ; Page, Stephen W ; Coaicetto, Flaminia
Abstract:
Doxapram is marketed as a respiratory stimulant and is used by some veterinarians to help with neonatal apnoea, especially in puppies delivered by caesarean. There is a lack of consensus as to whether the drug is effective and data on its safety are limited. Doxapram was compared to placebo (saline) in newborn puppies in a randomized, double‐blinded clinical trial using two outcome measures: 7‐day mortality rate and repeated APGAR score measurements. Higher APGAR scores have been positively correlated with survival and other health outcomes in newborns. Puppies were delivered by caesarean and a baseline APGAR score was measured. This was immediately followed by a randomly allocated intralingual injection of either doxapram or isotonic saline (of the same volume). Injection volumes were determined by the weight of the puppy and each injection was administered within a minute of birth. The mean dose of doxapram administered was 10.65 mg/kg. APGAR scores were measured again at 2, 5, 10 and 20 min. One hundred and seventy‐one puppies from 45 elective caesareans were recruited into this study. Five out of 85 puppies died after receiving saline and 7 out of 86 died after receiving doxapram. Adjusting for the baseline APGAR score, the age of the mother and whether the puppy was a brachycephalic breed, there was insufficient evidence to conclude a difference in the odds of 7‐day survival for puppies that received doxapram compared to those that received saline (p = .634). Adjusting for the baseline APGAR score, the weight of the mother, the litter size, the mother's parity number, the weight of the puppy and whether the puppy was a brachycephalic breed, there was insufficient evidence to conclude a difference in the probability of a puppy having an APGAR score of ten (the maximum APGAR score) between those that received doxapram compared to those that received saline (p = .631). Being a brachycephalic breed was not associated with an increased odds of 7‐day mortality (p = .156) but the effect of the baseline APGAR score on the probability of having an APGAR score of ten was higher for brachycephalic than non‐brachycephalic breeds (p = .01). There was insufficient evidence that intralingual doxapram provided an advantage (or disadvantage) compared to intralingual saline when used routinely in puppies delivered by elective caesarean and that were not apnoeic.
2023-10-01Seminars in fetal & neonatal medicine
Improving rates of successful extubation: Medications
Review
作者: Bruschettini, Matteo
This chapter focuses on the pharmacological management of newborn infants in the peri-extubation period to reduce the risk of re-intubation and prolonged mechanical ventilation. Drugs used to promote respiratory drive, reduce the risk of apnoea, reduce lung inflammation and avoid bronchospasm are critically assessed. When available, Cochrane reviews and randomised trials are used as the primary sources of evidence. Methylxanthines, particularly caffeine, are well studied and there is accumulating evidence to guide clinicians on the timing and dosage that may be used. Efficacy and safety for doxapram, steroids, adrenaline and salbutamol are summarised. Management of term infants, extubation following surgery, accidental and complicated extubation and the use of cuffed endotracheal tubes are presented. Overall, caffeine is the only drug with a substantial evidence base, proven to increase the likelihood of successful extubation in preterm infants; no drugs are needed to facilitate extubation in most term infants. Future studies might further define the role of caffeine in late preterm infants and evaluate medications for post-extubation stridor, bronchospasm or apnoea not responsive to methylxanthines.
100 项与 盐酸多沙普仑 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸功能不全 | 中国 | 1991-01-01 | |
| 呼吸功能不全 | 中国 | 1991-01-01 | |
| 呼吸暂停 | 日本 | 1976-02-14 | |
| 肺部疾病 | 美国 | 1965-06-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 繭窪醖蓋鏇繭鑰觸艱鑰(獵構蓋範構鬱積簾憲糧) = 願艱顧鑰鹹願壓憲醖蓋 壓淵淵齋襯窪齋築憲製 (鹽願醖憲鹹繭網範餘餘 ) 更多 | - | 2022-08-27 | ||
Ketodoxapram | 繭窪醖蓋鏇繭鑰觸艱鑰(獵構蓋範構鬱積簾憲糧) = 繭窪壓簾築鹹衊遞憲遞 壓淵淵齋襯窪齋築憲製 (鹽願醖憲鹹繭網範餘餘 ) 更多 | ||||||
N/A | - | 膚襯繭壓遞齋製願範廠(製範遞製鑰襯選窪憲築) = 鹽製衊襯鹹鏇範衊獵襯 餘醖網積鏇鹹選鹹鬱夢 (艱鬱襯積構夢蓋簾鬱衊 ) | - | 2019-09-01 | |||
临床4期 | 呼吸暂停 三线 | 85 | Doxapram dosing adjusted for gender and postmenstrual age (GrA) | (鬱鬱願製鏇願觸壓夢鑰) = 鹹鏇鑰築鏇積淵餘獵構 鬱範範獵築鹹鑰壓鏇遞 (選繭構餘鑰艱鏇網衊鹽 ) | - | 2016-12-01 | |
(Infants' weight alone (GrW)) | (鬱鬱願製鏇願觸壓夢鑰) = 窪積淵獵膚願鹹鹽鬱醖 鬱範範獵築鹹鑰壓鏇遞 (選繭構餘鑰艱鏇網衊鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用